Lipidomics Shared Resource
Lipidomics Shared Resource
批准号:
10377471
负责人:
Besim Ogretmen
金额:
$6.18万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-04-01 至 2024-03-31
关键词:
AllyBiologicalBiologyBloodBrainCancer BiologyCancer CenterCancer Center Support GrantCellsChemicalsClinicalClinical ResearchCommunitiesComplexCoupledData AnalysesDevelopmentDisciplineDoctor of PhilosophyDrug TargetingEducational workshopEquipmentFosteringFundingFutureGlycolipidsGlycoproteinsGlycosphingolipidsGoalsGrantImageImmunologyIndividualInternationalInvestigationIonsKidneyLeadershipLipidsLiquid substanceLiverLocationMalignant NeoplasmsMass Spectrum AnalysisMeasurementMedicalMetabolismMethodologyMethodsMissionMolecularMolecular AnalysisNonesterified Fatty AcidsOrganPharmaceutical PreparationsPhase I Clinical TrialsPhospholipidsPopulationPositioning AttributeProstaglandinsProtocols documentationPublicationsReagentResearchResearch DesignResearch PersonnelResolutionResource SharingResourcesRoleSamplingScienceScientistServicesSignal TransductionSourceSouth CarolinaSpecimenSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationSphingolipidsStructureSurfaceSystemTherapeuticTissuesTraining and EducationTumor BiologyTumor Cell BiologyUniversitiesWorkanaloganalytical methodanticancer researchbasebiomarker developmentcancer cellcancer initiationcellular imagingcost effectivedesigndetection limitdrug distributionimaging capabilitiesimprovedin vivoinhibitorinstrumentinstrumentationinterestlipid metabolismlipidomicsmass spectrometermembermitochondrial metabolismmolecular imagingnovelprogramstranslational studytumor progressiontumor xenograft
中文摘要
脂组学共享资源:摘要
英文摘要
LIPIDOMICS SHARED RESOURCE: SUMMARY
The mission of the Lipidomics Shared Resource (LSR) is to provide cost-effective advanced methodology,
state-of-the-art instrumentation, and expertise in the synthesis and analysis of bioactive lipids to Hollings Can-
cer Center (HCC) members. The scientific goal of the LSR is to provide resources for studying lipid metabolism
and signaling in cancer, for identifying bioactive lipids and their role in tumor cell biology, and for discovering
and evaluating drugs that target lipid metabolic processes. By providing deep exploratory as well as high
throughput lipidomic options to analyze cancer cells and tissues, combined with educational workshops, the
LSR fosters interactions among basic, clinical and population scientists at HCC. To remain at the leading edge
of an evolving field, since the last review, the LSR expanded services by investing in new equipment (Thermo
TSQ-50003, SCIEX Q-Trap triple quadrupole/ion trap, Advion TriVersa Nanomat) and transferring equipment
from the Cell & Molecular Imaging Shared Resource to LSR, adding MALDI imaging services to LSR (Bruker
Faltonics AutoFlex III linear MALDI, and AutoFLexIII MALDI TOF-TOF). During the current cycle, the LSR di-
rectly supported 45 cancer-related publications, three team science projects, multiple internally funded team-
based projects, three individual cancer grants, two translational studies, and one phase 1 clinical trial. Under
the leadership of Besim Ogretmen, PhD, the LSR has grown to become a nationally- and internationally-recog-
nized scientific resource with novel sophisticated methods for measurement and analysis of bioactive lipid mol-
ecules relevant to cancer initiation and progression. Ogretmen is a national leader in lipid biology with a partic-
ular focus on sphingolipids, including glycosphingolipids. The LSR has integrated MALDI imaging capability for
direct tissue analysis of sphingolipid species in tissues, drug distribution in tumor xenograft tissue and organs
(brain, kidney, liver), and structure confirmation of drug or metabolite of interest by collision-induced fragmenta-
tion. Thus, by combining mass spectrometry and MALDI imaging, this resource not only quantifies sphin-
golipids in tissues, but can also provide information about their cellular location and distribution in tissues. The
LSR is well poised to advance and support important emerging scientific disciplines in cancer research to HCC
members and the broader scientific community.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting AML Mitochondria by Ceramide
-
批准号:10546239
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2022
-
负责人:Besim Ogretmen
-
依托单位:
Sphingolipid Metabolism and Signaling in the Regulation of Senescence and Aging
-
批准号:10253130
-
项目类别:
-
资助金额:$36.98万
-
财政年份:2020
-
负责人:Besim Ogretmen
-
依托单位:
Ceramide Signaling in the Regulation of Head & Neck Cancer Cell Death and Therapy
-
批准号:9930853
-
项目类别:
-
资助金额:$1.62万
-
财政年份:2019
-
负责人:Besim Ogretmen
-
依托单位:
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
-
批准号:10411382
-
项目类别:
-
资助金额:$6.3万
-
财政年份:2018
-
负责人:Besim Ogretmen
-
依托单位:
Ceramide metabolism and the regulation of PD-L1 signaling to control metastasis and resistance to immunotherapy in TNBC
-
批准号:10801345
-
项目类别:
-
资助金额:$37.11万
-
财政年份:2018
-
负责人:Besim Ogretmen
-
依托单位:
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
-
批准号:9977980
-
项目类别:
-
资助金额:$34.2万
-
财政年份:2018
-
负责人:Besim Ogretmen
-
依托单位:
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
-
批准号:10222592
-
项目类别:
-
资助金额:$34.2万
-
财政年份:2018
-
负责人:Besim Ogretmen
-
依托单位:
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
-
批准号:10460230
-
项目类别:
-
资助金额:$33.51万
-
财政年份:2018
-
负责人:Besim Ogretmen
-
依托单位:
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
-
批准号:9441547
-
项目类别:
-
资助金额:$34.2万
-
财政年份:2018
-
负责人:Besim Ogretmen
-
依托单位:
Development of Novel Cancer Therapeutics by Targeting Sphingolipid Signaling
-
批准号:9072008
-
项目类别:
-
资助金额:$181.11万
-
财政年份:2016
-
负责人:Besim Ogretmen
-
依托单位:
Project 2: Regulation of Tumor Metastasis by Systemic S1P and Complement Signaling
-
批准号:9072014
-
项目类别:
-
资助金额:$29.99万
-
财政年份:2016
-
负责人:Besim Ogretmen
-
依托单位:
Development of Novel Cancer Therapeutics by Targeting Sphingolipid Signaling
-
批准号:9980696
-
项目类别:
-
资助金额:$174.77万
-
财政年份:2016
-
负责人:Besim Ogretmen
-
依托单位:
Mechanisms of sphingolipid analogue drug FTY720-mediated NSCLC tumor suppression
-
批准号:8585322
-
项目类别:
-
资助金额:$31.02万
-
财政年份:2013
-
负责人:Besim Ogretmen
-
依托单位:
Mechanisms of sphingolipid analogue drug FTY720-mediated NSCLC tumor suppression
-
批准号:9269533
-
项目类别:
-
资助金额:$31.02万
-
财政年份:2013
-
负责人:Besim Ogretmen
-
依托单位:
Mechanisms of sphingolipid analogue drug FTY720-mediated NSCLC tumor suppression
-
批准号:9076632
-
项目类别:
-
资助金额:$31.02万
-
财政年份:2013
-
负责人:Besim Ogretmen
-
依托单位:
COBRE in Lipidomics and Pathobiology
-
批准号:8714006
-
项目类别:
-
资助金额:$109.48万
-
财政年份:2012
-
负责人:Besim Ogretmen
-
依托单位:
COBRE in Lipidomics and Pathobiology
-
批准号:8514026
-
项目类别:
-
资助金额:$105.65万
-
财政年份:2012
-
负责人:Besim Ogretmen
-
依托单位:
COBRE in Lipidomics and Pathobiology
-
批准号:8305278
-
项目类别:
-
资助金额:$109.48万
-
财政年份:2012
-
负责人:Besim Ogretmen
-
依托单位:
COBRE in Lipidomics and Pathobiology
-
批准号:9098741
-
项目类别:
-
资助金额:$109.48万
-
财政年份:2012
-
负责人:Besim Ogretmen
-
依托单位:
Developmental Cancer Therapeutics
-
批准号:10589910
-
项目类别:
-
资助金额:$5.06万
-
财政年份:2009
-
负责人:Besim Ogretmen
-
依托单位:
海外基金